barzolvolimab
Phase 3Monoclonal antibody
barzolvolimab is one of 153 biologic programs targeting Urticaria. It is currently in Phase 3.
6
Indications
9
Total Trials
6
Active Trials
152
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Nereus
VVanda Pharmaceuticals
Phase 3
Xyzal
CChattem
Phase 3
Flovent
PParatek Pharmaceuticals Inc
Phase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
barzolvolimab
CCelldex Therapeutics
Phase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
OPA-15406
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Spontaneous Urticaria4 trials
1 more indication
Chronic Inducible Urticaria1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for barzolvolimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- CCelldex Therapeutics